Publication | Closed Access

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Metastatic Breast CancerProgesterone ReceptorBreast OncologyMedicineEstrogen ReceptorGynecologyBreast CancerCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer